Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
With
Hospital Clinic of Barcelona
Age
60–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Age ≥ 60 years
Informed, written consent form
To fully satisfy the criteria for one of the two following 2 groups:
1. for the AD group:
* Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers): Light to mild AD defined by Mini-Mental State Examination (MMSE) score between 15 and 27 (included).
* Documented positive visual read (as per EMA-approved procedures for each respective tracer) of an amyloid PET scan, which in the opinion of the principal investigator is consistent with a diagnosis of AD in the last 24 months.
* Lumbar puncture with core AD CSF biomarkers available in the last 24 months.
2. For the cognitively health group:
* Normal cognition as defined by the ALFA study cognitive workup (Molinuevo et al. 2016).
CONFIDENTIAL 17
\[18F\]-Flutemetamol PET scan performed in the context of the PET FLUTEMETAMOL-FDG/BBRC2015 study in the last 24 months.
Lumbar puncture with core AD CSF biomarkers preferably available in the last 24 months.
You may not be if
Past or present history of major brain disorders other than MCI or AD.
Contraindication to MRI scanning or conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
Participation in a clinical trial for a disease modifying drug for AD.
Hypoperfusion pattern not consistent with AD diagnosis, as assessed by ASL.
